Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech Stock
Biotech
Galectin's stock halves after phase 3 MASH trial misses goal
Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Gabrielle Masson
Dec 20, 2024 2:40pm
Lumos stock rockets on oral growth hormone phase 2 results
Nov 8, 2023 9:40am
Enochian distances itself from co-founder amid short attack
Jun 2, 2022 10:53am
Zymeworks rejects All Blue's $773M offer as 'opportunistic'
May 20, 2022 10:56am
With clinical holds lifted, Aprea embarks on 'show me' year
Mar 16, 2022 11:08am
vTv CEO resigns four months in and board member takes over
Mar 4, 2022 9:50am
